Aug 2026· Medicine· Vol 105· 0 citations· 11 references
Medicine
TL;DR
This case suggests that combining chemotherapy with programmed cell death protein 1 inhibition may provide rapid and effective tumor control in advanced non-small cell lung cancer patients with bulky, symptomatic metastases, while maintaining a manageable safety profile.
Abstract
Rationale: Despite available therapies, patients with advanced non-small cell lung cancer have a poor prognosis, highlighting the need for novel treatment strategies. The combination of immune checkpoint inhibitors and chemotherapy represents a promising approach. This case report describes the efficacy and safety of this combination in a patient with aggressive metastatic disease. Patient concerns: A 60-year-old male patient, who had undergone surgical resection for primary lung adenocarcinoma, presented with newly developed subcutaneous nodules and symptoms suggestive of adrenal involvement during routine follow-up. Diagnoses: Histopathological and imaging examinations confirmed recurrent lung adenocarcinoma with metastases to the subcutaneous soft tissues and the adrenal gland. Interventions: The patient received platinum-based doublet chemotherapy combined with pembrolizumab (an anti-programmed cell death protein 1inhibitor) as second-line systemic therapy. Outcomes: Following several treatment cycles, imaging revealed marked regression of metastatic lesions, with only minimal treatment-related adverse events reported. The patient achieved a durable clinical response. Lessons: This case suggests that combining chemotherapy with programmed cell death protein 1 inhibition may provide rapid and effective tumor control in advanced non-small cell lung cancer patients with bulky, symptomatic metastases, while maintaining a manageable safety profile. Further clinical trials are warranted to validate this approach.
The progress in the treatment modalities for SCLC is focused on and future perspectives involving novel therapeutic combinations, assessment of new targets, and strategies to overcome treatment resistance are discussed.
Xiangwei Cheng, Weibin Lv, Linfeng Wu et al.· Journal of Cancer Research a...· 0 citations
The level of evidence supporting the combined chemoradiotherapy approach is inferior to that for adjuvant chemotherapy, necessitating a selective strategy: radiotherapy should only be considered in cases when predictive models indicate a high likelihood of benefit.
Eduard A. Sarukhanov, Grigoriy V. Afonin, E. Smolenov et al.· Clinical review for general...· 0 citations
Abstract Introduction Primary salivary clear cell carcinoma (CCC) is a rare tumor of the minor salivary glands that is often seen as low-grade and responsive to resection. Limited data exist for its response to systemic chemotherapy or immune therapy. Case Presentation A 76-year-old male presented with recurrent, widel...
Samuel F. Schaeffer, M. Mirsky· Case Reports in Oncology· 0 citations
These findings support multidisciplinary care as the cornerstone of long-term survival in liver cancer as an integral component of immunomodulation, DC-CIK cell therapy remodels the tumor microenvironment to facilitate other treatments, making it a defining therapeutic decision for patients with advanced liver cancer.
Shan-Shan Chen, Yun-Qing Xie, Shao-Hua Xu et al.· Frontiers in Immunology· 0 citations
Background. Antitumor drug therapy plays a significant role in the treatment of metastatic colorectal cancer, increasing patient survival. The use of immuno-oncology agents in this treatment is limited, as most colorectal tumors are characterized by low immunogenicity. Cytokine gene therapy agents are gaining attention...
A. Ben, V. T. Zarkua· Lechaschi Vrach· 0 citations
This case demonstrates that even when HP-SCNEC abdominal lesions achieve deep remission through intensified immunotherapy combined with chemotherapy, patients remain at extremely high risk for early brain metastases, highlighting the “intracranial sanctuary” effect caused by the blood-brain barrier.
Jing Cui, Yu-Kai Gao· Frontiers in Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.